Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.

Oncogene - 9 Feb 2012

Gamble L D, Kees U R, Tweddle D A, Lunec J

Abstract excerpt

MYCN amplification is a major biomarker of poor prognosis, occurring in 25-30% of neuroblastomas. MYCN has contradictory roles in promoting cell growth and sensitizing cells to apoptosis. We have recently shown that p53 is a direct transcriptional target of MYCN in neuroblastoma and that p53-mediated apoptosis may be an important mechanism of MYCN-induced apoptosis. Although p53 mutations are rare in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Caspase 3
Share to Caspase 7
Share to N-Myc Proto-Oncogene Protein

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Oncogene Proteins

Share to Proto-Oncogene Proteins c-mdm2

Share to Spiro Compounds

Share to Tetracycline

Share to Tumor Suppressor Protein p14ARF

Source

Open in PubMed Open full text

Identifiers

PMID: 21725357
DOI: 10.1038/onc.2011.270
PMCID: PMC3191119

Genes

MYCN
MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.PMID 21725357Read ↗

Small-Molecule MDM2 Antagonists as a New Therapy Concept for NeuroblastomaSemantic proximity Read ↗

Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.Semantic proximity Read ↗

Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cells.Semantic proximity Read ↗

MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastomaSemantic proximity Read ↗

Mdm2 Deficiency Suppresses MYCN-Driven Neuroblastoma Tumorigenesis In VivoSemantic proximity Read ↗

Functional analysis of the p53 pathway in neuroblastoma cells using the small-molecule MDM2 antagonist nutlin-3.Semantic proximity Read ↗

Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression.Semantic proximity Read ↗

A p53 Drug Response Signature Identifies Prognostic Genes in High-Risk NeuroblastomaSemantic proximity Read ↗

Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents.Semantic proximity Read ↗

Crosstalk between MYCN and MDM2-p53 signal pathways regulates tumor cell growth and apoptosis in neuroblastomaSemantic proximity Read ↗

The p53 regulatory gene <i>MDM2</i> is a direct transcriptional target of MYCN in neuroblastomaSemantic proximity Read ↗

MYCN sensitizes human neuroblastoma to apoptosis by HIPK2 activation through a DNA damage response.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.